Literature DB >> 11303275

Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid.

H M Babcock1, D J Ritchie, E Christiansen, R Starlin, R Little, S Stanley.   

Abstract

We report a case of vancomycin-resistant Enterococcus faecium endocarditis that failed to respond to sequential monotherapy with chloramphenicol and quinupristin/dalfopristin but was successfully treated with oral linezolid.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11303275     DOI： 10.1086/319986

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  13 in total

1.  Enterococcal endocarditis: can we win the war?

Authors:  Jose M Munita; Cesar A Arias; Barbara E Murray
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

2.  [S2 Guideline for diagnosis and therapy of infectious endocarditis].

Authors:  C K Naber
Journal:  Z Kardiol       Date:  2004-12

Review 3.  Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.

Authors:  G M Eliopoulos
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

4.  Agents for the Treatment of Multidrug-resistant Gram-positive Endocarditis.

Authors:  Jennifer K Long
Journal:  Curr Infect Dis Rep       Date:  2005-07       Impact factor: 3.725

Review 5.  Infective endocarditis treated with linezolid: case report and literature review.

Authors:  E E Hill; P Herijgers; M-C Herregods; W E Peetermans
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-03       Impact factor: 3.267

Review 6.  Current concepts in antimicrobial therapy against select gram-positive organisms: methicillin-resistant Staphylococcus aureus, penicillin-resistant pneumococci, and vancomycin-resistant enterococci.

Authors:  Ana Maria Rivera; Helen W Boucher
Journal:  Mayo Clin Proc       Date:  2011-12       Impact factor: 7.616

7.  In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.

Authors:  George P Allen; Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Issues in the Management of Endocarditis Caused by Resistant Gram-positive Organisms.

Authors:  Martin E. Stryjewski; Vivian H. Chu; Christopher H. Cabell; Vance G. Fowler
Journal:  Curr Infect Dis Rep       Date:  2004-08       Impact factor: 3.725

9.  Efficacy of linezolid plus rifampin in an experimental model of methicillin-susceptible Staphylococcus aureus endocarditis.

Authors:  Charlene F Dailey; Paul J Pagano; Lewis V Buchanan; Jennifer A Paquette; Joseph V Haas; John K Gibson
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

10.  Medical treatment of endocarditis.

Authors:  Elias Abrutyn; Christopher H Cabell; Vance G Fowler; Bruno Hoen; José M Miro; Carlos A Mestres; Daniel J Sexton; G Ralph Corey
Journal:  Curr Infect Dis Rep       Date:  2007-07       Impact factor: 3.725
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.